A New Conception About Individualized Treatment Allocation for HCC (PTA4HCC)

Tang-Du Hospital

Status: Completed

Conditions: Resection; Transarterial Chemoembolization; HCC

Treatments: Procedure: TACE

Study type: Observational

Funder types: Other

Identifiers

NCT06008548

liulei

Details and patient eligibility

About

The current guidelines on hepatocellular carcinoma (HCC) aimed to build effective prognostic stratification strategies to guide therapeutic allocation; however, the current guidelines did not consider the simultaneous comparison of distinct therapies in similar populations. Here, the investigators aimed to develop and validate a new, integrated prognostic scheme for HCC patients using artificial intelligence (AI) to simulate the survival outcomes of patients allocated to different treatments.

Full description

Given that liver resection (LR) and transarterial chemoembolization (TACE) are the mainstay curative and palliative therapies for HCC, respectively, patients who underwent LR or TACE were included in the study. Various prognostic AI algorithms were modeled using data from a large multi-institutional cohort, where LR and TACE were considered independent factors. The C-index, Brier score (BS), and area under the receiver operating characteristic curve (auROC) were calculated to estimate the AI models.

Enrollment: 4,991 patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

• Diagnosed with HCC
• Receiving LR or TACE therapy
• Complete clinical information
• Preserved liver function (Child-Pugh Score [CPS] ≤ 7)
• PS 0-1

Exclusion Criteria

• Vascular invasion or extrahepatic spread;
• Ecompensated liver cirrhosis ;
• Younger than 18 years;
• Duration of follow-up of fewer than 30 days.

Trial design

4,991 participants in 2 patient groups

TACE group

Description:

Incorporated HCC patients underwent TACE therapy.

Treatment:

Procedure: TACE

Liver resection group

Description:

Incorporated HCC patients underwent liver resection therapy.